Vanguard files Amendment No. 9, 9.73% stake in MetLife
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
The Vanguard Group filed Amendment No. 9 to Schedule 13G reporting beneficial ownership of 64,749,341 MetLife (MET) common shares, representing 9.73% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 3,353,980 with shared voting power. It has sole dispositive power over 59,193,894 shares and shared dispositive power over 5,555,447 shares. The filing identifies Vanguard as an investment adviser and certifies the holdings were acquired and are held in the ordinary course, not to change or influence control.
The filing notes that Vanguard’s clients have the right to receive dividends and sale proceeds related to the reported securities, and that no single other person’s interest exceeds 5%.
Positive
- None.
Negative
- None.
FAQ
What did Vanguard disclose in its Schedule 13G/A for MET?
Vanguard reported beneficial ownership of 64,749,341 MetLife common shares, equal to 9.73% of the class as of 09/30/2025.
How large is Vanguard’s stake in MetLife (MET)?
Vanguard’s beneficial ownership is 64,749,341 shares, representing 9.73% of MetLife’s common stock.
What is the event date and amendment number in this filing?
Event date: 09/30/2025; this is Amendment No. 9 to Schedule 13G.
Did Vanguard state an intent to influence control at MetLife?
No. Vanguard certified the securities were acquired and are held in the ordinary course, not to change or influence control.